Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1
Open Access
- 5 May 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0154824
Abstract
An outbreak of influenza H1N1 in 2009, representing the first influenza pandemic of the 21st century, was transmitted to over a million individuals and claimed 18,449 lives. The current status in many countries is to prepare influenza vaccine using cell-based or egg-based killed vaccine. However, traditional influenza vaccine platforms have several limitations. To overcome these limitations, many researchers have tried various approaches to develop alternative production platforms. One of the alternative approach, we reported the efficacy of influenza HA vaccination using a baculoviral DNA vaccine (AcHERV-HA). However, the immune response elicited by the AcHERV-HA vaccine, which only targets the HA antigen, was lower than that of the commercial killed vaccine. To overcome the limitations of this previous vaccine, we constructed a human endogenous retrovirus (HERV) envelope-coated, baculovirus-based, virus-like-particle (VLP)–forming DNA vaccine (termed AcHERV-VLP) against pandemic influenza A/California/04/2009 (pH1N1). BALB/c mice immunized with AcHERV-VLP (1×107 FFU AcHERV-VLP, i.m.) and compared with mice immunized with the killed vaccine or mice immunized with AcHERV-HA. As a result, AcHERV-VLP immunization produced a greater humoral immune response and exhibited neutralizing activity with an intrasubgroup H1 strain (PR8), elicited neutralizing antibody production, a high level of interferon-γ secretion in splenocytes, and diminished virus shedding in the lung after challenge with a lethal dose of influenza virus. In conclusion, VLP-forming baculovirus DNA vaccine could be a potential vaccine candidate capable of efficiently delivering DNA to the vaccinee and VLP forming DNA eliciting stronger immunogenicity than egg-based killed vaccines.Keywords
Funding Information
- Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (314003-02-3-SB010)
- Korea Health Industry Development Institute (HI15C1685)
This publication has 45 references indexed in Scilit:
- Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerationsJournal of Translational Medicine, 2013
- Nuclear Export Signal and Immunodominant CD8+T Cell Epitope in Influenza A Virus Matrix Protein 1Journal of Virology, 2012
- A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferretsVaccine, 2011
- Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective ImmunityPLOS ONE, 2011
- Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virusProceedings of the National Academy of Sciences, 2010
- Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine developmentVirology Journal, 2010
- Influenza Vaccination and Mortality: Differentiating Vaccine Effects From BiasAmerican Journal of Epidemiology, 2009
- A Trivalent Virus-Like Particle Vaccine Elicits Protective Immune Responses against Seasonal Influenza Strains in Mice and FerretsPLOS ONE, 2009
- Pandemic Potential of a Strain of Influenza A (H1N1): Early FindingsScience, 2009
- Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza VirusJournal of Virology, 2007